OncoTherapy Science, Inc. (TYO:4564)

OncoTherapy Science Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	750	610	1,134	1,153	332
Revenue Growth (YoY)	22.95%	-46.21%	-1.65%	247.29%	5.06%
Cost of Revenue	1,253	1,465	1,810	2,770	1,689
Gross Profit	-503	-855	-676	-1,617	-1,357
Selling, General & Admin	289	261	287	294	281
Other Operating Expenses	5	4	144	142	-
Operating Expenses	294	265	431	436	281
Operating Income	-797	-1,120	-1,107	-2,053	-1,638
Interest Expense	-1	-	-	-	-
Currency Exchange Gain (Loss)	1	-5	-8	-14	-3
Other Non Operating Income (Expenses)	-18	-12	-18	-5	1
EBT Excluding Unusual Items	-815	-1,137	-1,133	-2,072	-1,640
Asset Writedown	-	-154	-21	-547	-10
Other Unusual Items	2	5	38	49	90
Pretax Income	-813	-1,286	-1,116	-2,570	-1,560
Income Tax Expense	2	2	2	1	1
Earnings From Continuing Operations	-815	-1,288	-1,118	-2,571	-1,561
Net Income	-815	-1,288	-1,118	-2,571	-1,561
Net Income to Common	-815	-1,288	-1,118	-2,571	-1,561
Shares Outstanding (Basic)	261	213	193	187	176
Shares Outstanding (Diluted)	261	213	193	187	176
Shares Change (YoY)	22.73%	10.45%	2.76%	6.31%	8.14%
EPS (Basic)	-3.12	-6.05	-5.80	-13.71	-8.85
EPS (Diluted)	-3.12	-6.05	-5.80	-13.71	-8.85
Free Cash Flow	-815	-1,229	-798	-2,529	-1,805
Free Cash Flow Per Share	-3.12	-5.78	-4.14	-13.49	-10.24
Gross Margin	-67.07%	-140.16%	-59.61%	-140.24%	-
Operating Margin	-106.27%	-183.61%	-97.62%	-178.06%	-493.37%
Profit Margin	-108.67%	-211.15%	-98.59%	-222.98%	-470.18%
Free Cash Flow Margin	-108.67%	-201.47%	-70.37%	-219.34%	-543.67%
EBITDA	-	-	-1,091	-2,037	-1,589
EBITDA Margin	-	-	-96.21%	-176.67%	-
D&A For EBITDA	-	-	16	16	49
EBIT	-797	-1,120	-1,107	-2,053	-1,638
EBIT Margin	-106.27%	-183.61%	-97.62%	-178.06%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.